Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) to present company overview at TD Cowen 44th Annual Healthcare Conference, offering insights into novel cancer immunotherapies. The presentation will be live webcasted on Bolt's website with replays available for 30 days post-event.

REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44^th Annual Healthcare Conference on Tuesday, Mar. 5, at 2:50 p.m. EDT (11:50 a.m. PDT) in Boston, Massachusetts.

A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event.

About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. BDC-1001 is currently in Phase 2 clinical development following the successful completion of a Phase 1 dose-escalation trial that demonstrated tolerability and early clinical efficacy. BDC-3042, an agonist antibody targeting Dectin-2, is expected to initiate a Phase 1 trial in the second half of 2023. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. Bolt Biotherapeutics is also developing multiple Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.

Investor Relations and Media Contact:

Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com

When will Bolt Biotherapeutics present a company overview at TD Cowen 44th Annual Healthcare Conference?

Bolt Biotherapeutics will present a company overview at TD Cowen 44th Annual Healthcare Conference on Tuesday, Mar. 5, at 2:50 p.m. EDT (11:50 a.m. PDT).

Where will the presentation take place?

The presentation will take place in Boston, Massachusetts.

How can I watch the presentation if I cannot attend in person?

You can watch the live webcast of the presentation on the Events and Presentations page of Bolt's website at www.boltbio.com.

For how long will the replays of the presentation be available?

Archived replays of the presentation will be available for 30 days following the event.